NewAmsterdam Pharma Stock (NASDAQ:NAMS)

Forecast Revenue Ownership Financials Chart

Previous Close

$30.55

52W Range

$21.14 - $42.20

50D Avg

$33.00

200D Avg

$34.00

Market Cap

$3.47B

Avg Vol (3M)

$1.31M

Beta

0.08

Div Yield

-

NAMS Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

NL

Employees

100

IPO Date

Feb 09, 2021

Website

NAMS Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 22
License Revenue	$93.50M

Fiscal year ends in Dec 25 | Currency in USD

NAMS Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$22.50M	$45.56M	$14.09M
Operating Income	-	$-176.29M	$-182.97M
Net Income	-	$-241.60M	$-176.94M
EBITDA	-	$-241.49M	$-176.86M
Basic EPS	$-1.72	$-2.56	$-2.15
Diluted EPS	$-1.72	$-2.56	$-2.15

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
VKTX	Viking Therapeutics, Inc.
CRNX	Crinetics Pharmaceuticals, Inc.
PRAX	Praxis Precision Medicines, Inc.
KYMR	Kymera Therapeutics, Inc.
CGON	CG Oncology Inc.
LGND	Ligand Pharmaceuticals Incorporated
AKRO	Akero Therapeutics, Inc.
IMVT	Immunovant, Inc.